Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
79.10
+0.27 (0.34%)
At close: Jun 27, 2025, 4:00 PM
79.00
-0.10 (-0.13%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
3.13
Revenue / Employee
$852,293
Employees
75,000
Market Cap
198.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
MRK News
- 7 hours ago - Merck: Don't Let Today's Bargain Opportunity Pass You By - Seeking Alpha
- 1 day ago - Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade) - Seeking Alpha
- 2 days ago - 40% Upside For Merck Stock? - Forbes
- 2 days ago - Merck's RSV shot for infants gets key approval despite RFK Jr.'s panel shakeup - Fast Company
- 2 days ago - ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season - Business Wire
- 3 days ago - RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants - CNBC
- 3 days ago - US CDC panel votes in favor of Merck's RSV antibody drug - Reuters
- 5 days ago - Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention - Business Wire